Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for XOLAIR
- E-B-FAHF-2, Multi OIT and Xolair for Food Allergy
- Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
- To Compare the PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult Subjects
- Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects
- Omalizumab Efficacy in Patients With Refractory Nasal Polyps
- Omalizumab Before Onset of Exacerbations
- Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair
- EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
- Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-55 With Peanut Allergy
- The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety
- Molecular Endotypes of Chronic Idiopathic Urticaria
- Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
- Xolair Interventional Study in ASD Patients With Comorbid Atopy
- Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection
- Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
- Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)
- Clinical Study Using Biologics to Improve Multi OIT Outcomes
- An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
- Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria
- A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
- A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps
- Multi OIT to Test Immune Markers After Minimum Maintenance Dose
- Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)
- Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy
- E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy
- Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
- Sputum-derived Cellular Targets After Xolair (Omalizumab)
- Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients
- Multi Immunotherapy to Test Tolerance and Xolair
- Preventing Asthma in High Risk Kids
- Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
- Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
- A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
- Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus
- Role of Anti-IgE in Severe Childhood Eczema
- Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction
- Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria
- Urticaria Facticia Treatment With Omalizumab (UFO)
- Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
- Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization
- Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
- Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils
- A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)
- Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)
- Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
- Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
- Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
- Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
- Cold Urticaria Treatment With Xolair
- The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
- Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome
- A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
- Xolair Enhances Oral Desensitization in Peanut Allergic Patients
- A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
- A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
- Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
- Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage
- OIT and Xolair® (Omalizumab) in Cow's Milk Allergy
- A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy
- Omalizumab in Non-atopic Asthma
- Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis
- The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
- Xolair Treatment for Milk Allergic Children
- Omalizumab in the Treatment of Peanut Allergy
- Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
- A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
- Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
- A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
- Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels
- Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
- An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
- Non-invasive Measures of Effects of Xolair in Asthma
- The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
- Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
- The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils
- The Effect of Xolair (Omalizumab) on Allergy Blood Cells
- A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels
- The Effect of Omalizumab on Responses to Cat Allergen Challenge
- Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis
- Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
- Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization
- A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
- Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
- Efficacy and Safety of Omalizumab in Bullous Pemphigoid
- A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)
- Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis
- A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
- Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
- Cell Biology of Steroid Resistant Asthma
- Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
- A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
- Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab
- Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma
- A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
- Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
- Omalizumab to Treat Hyper-IgE (Job's) Syndrome
- A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma
- Effect of Xolair on Airway Hyperresponsiveness
- Immune Dysfunction in Allergic Asthma
- Effect of Anti-IgE in Non-Allergic Asthma
- Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
- Effect of Anti-IgE in Chronic Urticaria
- A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
- Xolair in Patients With Chronic Sinusitis
- A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma
- An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g
- A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)
- A Safety and Efficacy Study of Xolair in Peanut Allergy
- Omalizumab to Treat Eosinophilic Gastroenteritis
Clinical trials list
click for details